CERSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
CERUS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$2.22+0.04 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $445.25M
- P/E (TTM)
- –
- Dividend yield
- –
CERUS CORP revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $221.55M | $216.56M | $206.13M | $199.19M | $192.51M | $185.14M | $180.27M | $176.23M | $169.98M | $163.76M | $156.37M | $153.63M | 100.0% | +15.1% |
| Government Contract | – | – | $27.67M | $26.78M | $23.88M | $21.64M | $21.05M | $21.68M | $24.52M | $27.96M | $30.43M | $31.14M | – | – |
By region
From the segment and revenue-disaggregation notes of Cerus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.